Baird Medical Investment Holdings Limited (BDMD) Aandelenanalyse

Bedrijfsoverzicht

Baird Medical Investment Holdings Limited is engaged in the research, development, manufacturing, and sales of microwave ablation and other medical devices within the People's Republic of China. The company operates specifically within the Healthcare sector, focusing on the Medical Devices industry where it specializes in offering microwave ablation apparatus and needles, as well as long microwave ablation needles. In terms of scale, the entity possesses a market capitalization of $65.00M and generates an annual revenue of $31.86M, supported by a workforce of 143 employees. These valuation and revenue figures indicate that Baird Medical Investment Holdings Limited functions as a mid-sized player in the Chinese medical device market, suggesting a company that has established a specific niche rather than dominating the broader global healthcare landscape.

Financiële gezondheid

The company reports a trailing twelve-month revenue of $31.86M, yet it recorded a net income of $-3,170,793, while maintaining a positive EBITDA of $919,415. The significant disparity between the positive EBITDA and the negative net income reveals a cost structure where non-operating expenses or interest costs are substantial enough to erade operating profits into a net loss. Despite the net loss, the company generates free cash flow of $2.52M, which provides a degree of financial flexibility to fund operations without immediate reliance on external equity financing. The balance sheet is heavily leveraged, characterized by a debt load of $22.56M against cash reserves of $2.50M, resulting in a debt-to-equity ratio of 63.33. Short-term liquidity appears manageable given a current ratio of 1.71, indicating that current assets are more than sufficient to cover current liabilities. However, the return on equity stands at -8.0% and the return on assets is -0.2%, metrics that collectively reveal that management effectiveness in generating shareholder value is currently challenged by the prevailing net loss position.

Waarderingsbeoordeling

Trailing and forward P/E ratios are listed as N/A, a valuation characteristic that implies earnings are currently negative and prevents the use of standard earnings-based multiples for comparison. The price-to-book ratio is 1.32, indicating that the market values the company at a premium of 32% over its net book value. When looking at alternative valuation metrics, the price-to-sales ratio is 2.04 and the EV/EBITDA stands at 72.97, suggesting that investors are pricing the company based on sales potential and cash generation rather than current profitability. The stock has exhibited significant volatility, trading between a 52-week high of $7.26 and a 52-week low of $0.76. Given these bounds, the current price sits at a level that reflects substantial downside from the recent highs while remaining well above the yearly lows. The beta value is -1.16, a unique metric suggesting an inverse correlation to the broader market where the stock price tends to move in the opposite direction of market indices.

Growth & Income

Revenue growth year-over-year is -39.4%, while earnings growth is N/A due to the negative net income position, meaning the company is currently contracting in terms of top-line sales rather than expanding. Since the company is not a dividend payer with a yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders but instead retains all earnings to fund its operations and potentially reduce its high debt load. The absence of a dividend program aligns with the company's need to reinvest any available cash flow into its research and development activities or to service its significant debt obligations. Overall, the growth and income profile presents a high-risk scenario with declining revenue and no current income distribution, relying entirely on future operational improvements to stabilize financial performance.